Trial PaperMajor Depressive Disorder (MDD)Bipolar DisorderDepressive DisordersNeurocognitive DisordersKetamine

Single Ketamine Infusion and Neurocognitive Performance in Bipolar Depression

This open-label study (n=18) assessed antidepressant efficacy and neurocognitive performance of intravenous ketamine (35mg/70kg) in patients with bipolar depression (BD) and found that around half the patients responded to treatment. Independent of depressive symptoms, ketamine generally improved impairments in their cognitive performance, on measures related to psychomotor speed, verbal abilities, and executive functioning.

Authors

  • Permoda-Osip, A.
  • Kisielewski, J.
  • Bartkowska- Sniatkowska, A.

Published

Pharmacopsychiatry
individual Study

Abstract

Methods

We estimated neurocognitive performance using the trail making test (TMT) and the Stroop color-word interference test before, and on the 3rd day after a single infusion of ketamine, in 18 bipolar depressed patients receiving mood-stabilizing drugs.

Results

The performance on all tests significantly improved on the 3rd day after ketamine infusion which correlated positively with baseline intensity of neuropsychological impairment and was not associated either with baseline intensity of depression or reduction of depressive symptoms after 3 or 7 days.

Discussion

The results suggest that in such population of patients, single ketamine infusion may improve neuropsychological performance independently of antidepressant effect.

Available with Blossom Pro

Research Summary of 'Single Ketamine Infusion and Neurocognitive Performance in Bipolar Depression'

Introduction

Earlier research has shown that a single subanaesthetic infusion of ketamine (0.5 mg/kg) can produce a rapid antidepressant effect in treatment-resistant unipolar depression and, when added to mood-stabilising drugs, in bipolar depression. Cognitive deficits are a prominent feature of depressive episodes and of bipolar disorder more generally; previous studies have reported mixed effects of ketamine on cognition, with some transient impairments after a single infusion and improvements reported after serial infusions in treatment-resistant major depression. Permoda-Osip and colleagues set out to examine whether a single ketamine infusion would alter neurocognitive performance in patients with bipolar depression who were maintained on mood-stabilising medication. Specifically, the study measured cognitive performance before and on the third day after infusion and tested whether any cognitive changes related to baseline depression severity or to the antidepressant response to ketamine.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

See Pro PlansAlready have an account? Sign in

Study Details

Related Clinical Trial

Completed

Single IV Ketamine for Bipolar Depression: Open Neurocognitive Pilot Study (Permoda-Osip / Rybakowski, Poznan Poland)

Open single-arm pilot study of a single IV ketamine infusion in bipolar depression with neurocognitive outcomes (Pharmacopsychiatry 2015 Mar; Permoda-Osip A, Kisielewski J, Bartkowska-Sniatkowska A, Rybakowski JK; Department of Adult Psychiatry, Poznan University of Medical Sciences, Poland; PMID 25347227; DOI 10.1055/s-0034-1394399). n=18 bipolar I/II inpatients with a depressive episode (HDRS-17 ≥18). Intervention: single IV ketamine 0.5 mg/kg over 40 min. Neurocognitive battery assessed at baseline and 7 days post-infusion: Wisconsin Card Sorting Test, Stroop Colour–Word Test, Trail Making Test A/B, verbal fluency. HDRS-17 assessed at baseline, day 1, and day 7. No control arm. No CT.gov registration; no registration number reported. CT.gov PMID reverse-lookup: 0 hits.

Started
Type
interventional
Randomized
No
Registry ID
RYBAKOWSKI-2014-PHARMACOPSYCHIATRY-KETAMINE-BIPOLAR-POLAND

References (1)

Papers cited by this study that are also in Blossom

A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression

Diazgranados, N., Ibrahim, L., Brutsche, N. E. et al. · JAMA Psychiatry (2010)

943 cited

Cited By (7)

Papers in Blossom that reference this study

Neurocognitive effects of repeated ketamine infusions in comorbid posttraumatic stress disorder and major depressive disorder

Albott, C. S., Lim, K. O., Erbes, C. et al. · Journal of Affective Disorders (2022)

A Systematic Review of Neurocognitive Effects of Subanesthetic Doses of Intravenous Ketamine in Major Depressive Disorder, Post-Traumatic Stress Disorder, and Healthy Population

Shiroma, P. R., Velit-Salazar, M. R., Vorobyov, Y. · Clinical Drug Investigation (2022)

9 cited
Ketamine in Bipolar Disorder: A Review

Wilkowska, A., Szałach, L., Cubała, W. J. · Neuropsychiatric Disease And Treatment (2020)

Antidepressant and neurocognitive effects of serial ketamine administration versus ECT in depressed patients

Basso, L., Bönke, L., Aust, S. et al. · Journal of Psychiatric Research (2020)

Antidepressant, anxiolytic and procognitive effects of subacute and chronic ketamine in the chronic mild stress model of depression

Papp, M., Gruca, P., Lason-Tyburkiewicz, M. et al. · Behavioural Pharmacology (2017)

55 cited
Administration of ketamine for unipolar and bipolar depression

Kraus, C., Rabl, U., Vanicek, T. et al. · International Journal of Psychiatry in Clinical Practice (2017)

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants

Abdallah, C. G., Averill, L. A., Krystal, J. H. · Annals of the New York Academy of Sciences (2015)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

See Pro PlansSign in
Single Ketamine Infusion and Neurocognitive... — Research Summary & Context | Blossom